Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection
- PMID: 2995536
- PMCID: PMC2187857
- DOI: 10.1084/jem.162.4.1304
Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection
Abstract
Three herpes simplex virus type I (HSV-I) glycoproteins of apparent molecular masses 103, 63, and 115 kD have been purified using virus-specific monoclonal antibodies (mAb) G8D1, C2D2, and T157, respectively. Both G8D1 and C2D2 neutralize HSV-I in vitro and passively protect CBA mice against HSV-I infection in vivo, whereas T157 is neither neutralizing nor passively protective. However, mice given a single subcutaneous injection of 30 micrograms 115 kD glycoprotein in saline were completely protected against lethal challenges of HSV-I administered intraperitoneally or in the footpad 7 d after immunization. In contrast, mice similarly immunized with 103 or 63 kD glycoproteins were only partially protected. The prophylactic immunity was correlated with an early induction of specific antibody, which became even more evident 3 d after virus challenge. There was a remarkable similarity in antibody isotype distribution between the responses to 115 kD glycoprotein and to heat-inactivated intact HSV-I. However, the prechallenge sera from 115 kD glycoprotein hyperimmunized mice were again neither virus-neutralizing nor passively protective. All three glycoproteins induced only low levels of delayed-type hypersensitivity (DTH). Pretreatment of mice with cyclophosphamide significantly enhanced DTH to 115 kD and 103 kD glycoproteins in the absence of antibody, but failed to confer significant immunity, indicating that DTH alone is insufficient for protection. Splenic and lymph node Ig- (B cell-depleted) cells from mice protectively immunized with 115 kD glycoprotein could adoptively transfer effective protection and enhance a virus neutralizing antibody response in normal recipients challenged with a lethal dose of HSV-I. Both the protection and the ability to enhance neutralizing antibody were diminished when the cells were treated with mAb GK 1.5 and complement. These results therefore demonstrate that the 115 kD glycoprotein, though not apparently containing accessible epitopes for the induction of virus-neutralizing antibody, possesses determinants capable of activating helper T cells. These L3T4+ cells confer strong protective immunity by enhancing protective antibody upon challenge infection, probably through associative help.
Similar articles
-
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.Infect Immun. 1981 Oct;34(1):192-9. doi: 10.1128/iai.34.1.192-199.1981. Infect Immun. 1981. PMID: 6271681 Free PMC article.
-
Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.J Med Virol. 1985 Sep;17(1):9-18. doi: 10.1002/jmv.1890170103. J Med Virol. 1985. PMID: 2995573
-
Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.J Gen Virol. 1985 May;66 ( Pt 5):1073-85. doi: 10.1099/0022-1317-66-5-1073. J Gen Virol. 1985. PMID: 2582080
-
Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S924-34. doi: 10.1093/clind/13.supplement_11.s924. Rev Infect Dis. 1991. PMID: 1664130 Review.
-
Live vaccinia virus recombinants expressing herpes simplex virus genes.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S898-903. doi: 10.1093/clind/13.supplement_11.s898. Rev Infect Dis. 1991. PMID: 1664124 Review.
Cited by
-
Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B.J Virol. 1990 Nov;64(11):5277-83. doi: 10.1128/JVI.64.11.5277-5283.1990. J Virol. 1990. PMID: 1698994 Free PMC article.
-
Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection.Clin Exp Immunol. 1987 Nov;70(2):276-82. Clin Exp Immunol. 1987. PMID: 2827921 Free PMC article.
-
Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.J Virol. 2008 Dec;82(23):11792-802. doi: 10.1128/JVI.00692-08. Epub 2008 Sep 17. J Virol. 2008. PMID: 18799581 Free PMC article.
-
Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: cytotoxic T cells.J Virol. 1987 Mar;61(3):726-34. doi: 10.1128/JVI.61.3.726-734.1987. J Virol. 1987. PMID: 3027400 Free PMC article.
-
Functional cross-reactivity between the glycoprotein B of herpes simplex virus type 1 and Epstein-Barr virus.Immunology. 1989 Jan;66(1):14-9. Immunology. 1989. PMID: 15493256 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical